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Abstract:  
The main objective of the present study was to 
test the hypothesis that exogenous insulin 
would enhance colon carcinogenesis. Thirty-
six female F344 rats, fed ad libitum a low fat 
rodent chow, received a single azoxymethane 
injection (20 mg/kg), and were randomized a 
week later to two groups. Control rats were 
given 5 days a week a s.c. saline injection, and 
experimental rats were given ultralente bovine 
insulin, 20 U/kg. The promoting effect of 
insulin injections was assessed by the 
multiplicity (number of crypts) of aberrant 
crypt foci after 100 d of treatment (72 
injections). The rats given insulin ate more and 
were heavier than controls (215 ± 11 vs. 182 ± 
7 g, p<0.001). Insulin injections also increased 
the amount of abdominal fat, the plasma 
triglycerides, and the insulinemia, and 
decreased blood glucose (all p<0.05). The 
number of aberrant crypt foci was the same in 
both groups, but their multiplicity was 
significantly increased by the insulin injections 
(2.8 ± 0.3 vs. 2.5 ± 0.2 crypt/focus in controls, 
p=0.007). Besides, the proportion of 
sialomucin producing foci was higher in 
insulin injected rats than in controls (p=0.04). 
These data show that exogenous insulin can 
promote colon carcinogenesis in rats, and 
suggest that lifestyle and diets leading to low 
blood insulin might protect humans against 
colorectal cancer. 
 
Introduction 
 
 The current hypothesis linking diet and 
colon cancer is that a high fat, low fiber and 
low calcium diet increases the cancer risk, by 
increasing the concentration of promoting bile 
acids in the lumen of the gut (1). However 
randomized intervention trials assessing the 
recurrence of polyps in volunteers given high-
fiber low-fat diets do not support this 
hypothesis (2, 3). Although most studies focus 
on luminal factors in the fecal stream, it is also 
possible that the risk factor reaches the colonic 
cells by way of the general circulation (4). The 
major risk factors for colorectal cancer are the 
followings: sedentary lifestyle, high caloric 
intake, and diets high in fat, sucrose and 
ethanol, and low in fiber, resistant starch and n-
3 polyunsaturated fatty acids (1, 4). These 
factors are associated with elevated serum 
triglycerides and plasma glucose (5). High 
blood glucose and lipids influence circulating 
hormones, such as insulin, and can lead to 
insulin resistance, abdominal obesity, and 
eventually, non-insulin dependant diabetes (5). 
McKeown-Eyssen speculated that blood 
triglycerides, glucose, or insulin could promote 
cancer development (5). The idea was later 
supported by other reviews on insulin and 
colon cancer (6), or insulin and breast cancer 
(7, 8). We thus decided to study the direct 
effect of repeated insulin injections on rat colon 
carcinogenesis. 
 Promotion of cancer was assessed with 
the aberrant crypt focus (ACF) assay (9). ACF 
are putative precursors of colon cancer (10), 
specifically induced by colon carcinogens (11), 
promoted by promoting diets (12), inhibited by 
inhibitors of carcinogenesis (13). In rodents 
and humans, ACF display mutations and 
histologic changes observed in colonic tumors 
(14, 15, 16), and the growth of ACF correlates 
with the adenocarcinoma yield (17, 18, 19). 
The number of ACF per animal is an assay for 
initiators of colon cancer, although the number 
of crypts per focus (multiplicity) is a measure 
of promotion effect (17, 19, 20).  
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Materials and Methods. 
 
Animals and Treatments.  
 Thirty-six five-week-old female F344 
rats were obtained from Iffa-Credo (Lyon, 
France). They were acclimatized to the colony 
for one week, housed two rats per stainless 
steel wire drop-bottom cage, at 22°C with 
light-dark cycle 12h-12h, "day" starting at 7h30 
a.m., and fed a laboratory chow (6% fat, UAR, 
Villemoisson, France) and water ad libitum. 
The rats were initiated between 9 and 10 a.m. 
with a single i.p. injection of azoxymethane 
(Sigma, St.Quentin, France) at a dose of 20 
mg/kg in NaCl 9 g/l. They were randomly 
allocated to the treatments 7 d later. Rats in the 
control group were given subcutaneous 
injection of sterile saline (NaCl 9 g/l, 2.5 
ml/kg, id est 0.21 to 0.52 ml/rat). In the 
experimental group they were given s.c. 
injection of insulin (20 U/kg/d, UltralenteMC 
Novo Nordish Pharm., Boulogne, France, 
containing per ml 40 U bovine insulin and 0.08 
mg zinc) diluted with saline (8 U/ml in NaCl 9 
g/l). Injections were given five times per week, 
between 8h30 and 9 a.m.. A preliminary 
experiment showed that, provided they have 
free access to food, the rats may be given 
insulin up to 48 U/kg/d without major 
problems. Food intake, water intake and body 
weight were measured weekly. The animals 
were sacrificed 106 d after the carcinogen 
injection, 99 d after the first insulin injection, 
the day of the 72nd insulin injection, by 
cervical dislocation between 2 and 3h15 p.m.. 
Blood was taken from the heart, the abdominal 
fat was excised and weighed, and the colon 
was measured, and kept in formalin for ACF 
scoring. 
 
Assay of Blood Insulin, Glucose and 
Triglycerides.  
 Blood samples (1.5 ml) were collected 
by cardiac puncture in a syringe containing 5 µl 
heparin within 1 min after death, within 5h30 
and 6h15 after the last insulin injection. After 
centrifugation for 10 min at 1300 g the plasma 
was divided in coded microtubes kept at -80°C 
for further analyses. Insulin was measured by 
radioimmunoassay, using a kit designed for 
human plasma, giving a 100% cross-reaction 
with bovine and rat insulin (Insik-5, Sorin 
Biomedica, Antony France). Glucose and 
triglycerides were measured by enzymatic-
spectrophotometric methods (kits PAP-500 and 
-150, BioMérieux, Marcy France).  
 
Assay of Aberrant Crypt Foci.  
 ACF were scored 106 d after the 
carcinogen injection using the procedure 
described by Bird (10). Immediately after 
sacrifice, colons were removed and flushed 
with Kreb's Ringer solution (Sigma), then 
opened longitudinally and fixed flat between 
coded filter paper in 10% buffered formalin 
(Sigma). The colons were stained with 
methylene blue (0.1 %) for 10-15 min, then the 
mucosal side was observed at 32 x 
magnification. ACF were distinguished by their 
slit-like opening, increased staining, size and 
pericryptal zone. The multiplicity (number of 
crypts per ACF) was recorded for each ACF in 
each colon. Those were scored blindly by a 
single observer (C.J.).  
 After ACF methylene-blue scoring, the 
colons were rinsed then stained with high-iron 
diamine Alcian blue procedure to determine 
the type of mucin secretion (21). As already 
described (22, 23), the normal crypts in the 
proximal part of rat colon were stained blue 
(sialomucin). The normal crypts were stained 
dark brown (sulphomucin) in the distal colon, 
like in the normal human colorectal mucosa 
(22). ACF mucus staining was examined in this 
distal part (length 6.8 ± 0.3 cm in controls vs 
7.1 ± 0.9 cm insulin rats, p=0.1). The 
sialomucin secreting blue ACF were easily 
identified against the background of normal 
brown crypts. It has been suggested that a shift 
from sulphomucin to sialomucin production 
may represent an early feature of malignancy 
(22, 23). Colons were scored again blindly by a 
single observer (G.P.), to determine the type of 
mucin secreted by ACF. 
 
Statistics.  
 Data are given as mean ± standard 
deviations. The statistical analysis of ACF 
assay for colon cancer promotion was based on 
ACF multiplicity as defined by the mean 
number of aberrant crypts per focus (19). Data 
were examined by two-sided Student's t-test, or 
Welsh's test when variances were unequal. 
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Results 
 
Weights.  
 Rats given insulin grew faster than 
controls as shown on fig. 1. The difference 
reached significance on day 28 (p=0.015) and 
after. The food intake also was higher in 
insulin injected rats, even before they become 
heavier than control, e.g., between days 20 and 
23, they ate (mean ± SD) 16.6 ± 0.9 vs. 13.7 ± 
0.4 g/d respectively (p<0.001). Differences in 
food intake, water intake, fecal output, and 
body weight remained significant at all time 
points (data no shown), except during 
weekends: the injections were not done 
Saturday and Sunday, and rats in the insulin 
group tended to eat less than controls those 
days, e.g., 13.0 ± 0.7 vs. 14.1 ± 0.7 (p=0.05) 
between days 17 and 20. As shown on fig. 1 
the body weight difference between groups 
increased particularly during the last week, but 
weights were taken after 2 p.m. instead of 8h30 
a.m. usually. We guess that control rats do not 
eat during daytime (and can loose weight via 
fecal excretion), while insulin injected rats eat 
mostly between 9 a.m. and 2 p.m., i.e., just 
after the insulin injection. 
 
Fig. 1. Mean body weights of F344 female rats during 
daily injections of saline or insulin, starting 0 day. 
  
 On the day of sacrifice, the rats given 
insulin had more abdominal fat (10.4 ± 1.8 vs. 
7.7 ± 1.3 g), and a longer colon (13.8 ± 1.1 vs. 
12.5 ± 0.7 cm) than controls. These differences 
were significant (both p<0.005), but only the 
difference between abdominal fat remained so 
after adjustment for body weight (p<0.05). 
 
Blood Values.  
 On the day of sacrifice, about 6h after 
the last insulin injections, the blood insulin was 
higher in rats given insulin than in controls 
(440 ± 230 vs. 80 ± 25 µU/ml, p<0.0001). The 
blood glucose was lower in rats given insulin 
than in controls (4.2 ± 1.2 vs. 10.8 ± 1.6 
mmol/l, p<0.0001). The blood triglycerides 
were higher in rats given insulin than in 
controls (1.19 ± 0.25 vs. 0.97 ± 0.21 mmol/L, 
p=0.03). 
 
Promotion of ACF.  
 A total of 9355 ACF was detected in 
the 36 colons. The number of ACF per colon, 
which is not associated with tumor promotion, 
was the same in both groups (see Table 1). By 
contrast, the crypt multiplicity (or number of 
crypts/focus), a predictor of the tumor 
incidence, was higher in insulin treated rats 
than in controls (an 11 % increase, p=0.007). 
The number of large ACF, containing 7 crypts 
or more, which is another measure for ACF 
promotion, was higher in rats given insulin 
than in controls, with borderline significance 
(p=0.056). Thus data show that ACF grew 
faster in rats given insulin. 
 
Table 1. Effect of repeated insulin injections 
on aberrant crypt foci (ACF) in F344 rats after 
a single azoxymethane injectiona 
 
 
Group n ACF Multiplicity Large 
  /Rat crypts/ACF ACF b 
 
      
Saline 19c 259 ±78 2.49 ±0.21 7.5± 5.4  
Insulin 17 260 ±66 2.76 ± 0.33 10.8±4.5 
  
p value  0.98 0.007  0.056  
 
a: 72 insulin injections (20 U/kg) were given during 106 
days after a single azoxymethane injection (20 mg/kg) 
b: Large ACF: > 6 crypts 
c: Values are means ± SD; n, no. of rats;  
 
Nature of Mucus.  
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 The proportion of ACF excreting 
sialomucin was higher in insulin injected rats 
than in controls (43 ± 11 vs. 34 ± 8%, 
p=0.038), which suggests enhanced 
carcinogenesis. The proportion of large ACF 
excreting sialomucin was not changed by 
insulin. As shown on fig. 2, the proportion of 
sialomucin excreting ACF in the distal colon 
(mean 7 cm from anus) increased with ACF 
multiplicity. The correlation between the 
proportion of sialomucin marked ACF and the 
number of crypt per ACF was very high 
(r=0.99, p<0.0001). Thus, the sialomucin might 
just be another marker for large ACF. 
 
Fig. 2. Type of mucus produced by the aberrant crypt 
foci in the distal colon of rats according to their 
multiplicity. Percentage of ACF/ total ACF, secreting 
sialomucins, sulphomucins, or both types of mucins 
together. Data are based on 2444 ACF. 
 
Discussion. 
 
 The results of this study show that 
exogenous insulin leads to increased food 
intake, higher body weight and more 
abdominal fat, increased levels of plasma 
insulin and triglycerides, and reduced levels of 
plasma glucose. Insulin also increased the 
growth of aberrant crypt foci, with more crypts 
per ACF, and more large ACF per colon in 
insulin treated rats than in controls. Thus, 
insulin injections promoted colon carcinogene-
sis in this model. We also observed more 
sialomucin producing ACF in insulin treated 
rats than in controls. This might either suggest 
a more advanced phenotype (22, 23), or simply 
reflect the increased size of ACF.  
 A recent report by Tran et al. also 
shows that insulin is a colon tumor promoter in 
rats (24). After azoxymethane initiation and 
daily injections of insulin, the fraction of rats 
with colon adenomatous polyps was greater in 
rats receiving insulin than in rats receiving 
saline (79% vs. 50% respectively, p<0.05). The 
number of tumors per rat was also greater in 
the insulin group (2.0 vs. 0.7, p<0.05). Insulin 
did not increase body weight gain (24). Design 
differences between Tran's study and this one 
may explain the discrepancies in body weight 
gain and tumor outcome. Tran et al. used male 
rats (vs. female here), starting at 240 g body 
weight (vs. 85 g), fed an AIN93M diet (vs. 
rodent chow), given medium-acting porcine 
insulin (vs. long-action bovine) at 15 U/kg for 
132 days (vs. 20 U/kg for 100 d), after two 15 
mg/kg azoxymethane injections (vs. a single 
dose 20 mg/kg), with a light cycle shifted 6 h 
earlier than daylight (24). It is surprising that in 
Tran et al. study the insulin did not increase 
body weight, but it may be explained by 
differences in starting weight, gender, diet and 
insulin quickness. Although both studies show 
a significant promotion of carcinogenesis by 
insulin, at first glance the magnitude of effect 
appears smaller in the present study. However 
the crypt multiplicity increased here by a 1.11 
factor, which may be compared to the 1.20 
increase published by Zhang et al. (17) and 
Magnuson et al. (19). According to their data, 
the diets that increase the crypt multiplicity by 
1.2 at 100 d also increase the adenocarcinoma 
incidence by 3 later (17, 19). This increase is 
higher than the 1.6 increased tumor incidence 
observed by Tran (24). Thus, the promotion 
potency of insulin in both studies may be 
similar. 
 Previous reports show that insulin is a 
growth factor for rats and for tumors. Daily 
insulin injections (25 U/kg for 28 d) increase 
body weight, fat tissue weight, and fat cell size 
in female rats (25). Daily insulin injections to 
hypophysectomized rats enable the growth of 
liver tumors, initiated by dietary methyl-
dimethyl-aminobenzene (26). Conversely, 
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diabetes induced by alloxan in female rats 
previously initiated with dimethylbenzenthra-
cene produces the rapid regression of 90% of 
established mammary tumors. These tumors 
were shown to be insulin dependent in vitro 
(27).  
 
Exogenous insulin may promote tumor growth 
by at least three mechanisms.  
- First, exogenous insulin increases food intake 
and weight gain. Overfeeding and overweight 
increase, and caloric restriction decreases, 
carcinogenesis in many studies (28). 
Overfeeding modifies the hormonal balance 
and increases the energy available through the 
circulation for neoplastic cells. 
- Second, exogenous insulin leads to 
hyperinsulinemia, which may directly promote 
tumor growth (27), for instance by easing the 
uptake of nutrients by tumor cells.  
- Last, insulin may modify other blood-borne 
factor(s), for instance the insulin-like growth 
factor IGF1. Most colon cell lines have 
receptors for IGF1, and high fat diets induce 
both insulin and IGF1 resistance in rats (29).  
A study in pair-fed rats receiving exogenous 
insulin, but as many calories as controls, might 
tell if hyperinsulinemia by itself can promote 
tumors. In human beings, however, 
hyperinsulinemia is always associated with 
hyperphagia. 
 Diets high in calories, fat, sucrose, 
fructose, amylopectin starch, and low in fibers, 
resistant starch and n-3 unsaturated lipids, 
favor the insulin resistance syndrome in 
rodents. These diets increase blood insulin, and 
lead to abdominal fat store,  obesity, and non-
insulinodependant diabetes in many animal 
models (30, 31, 32, 33), and probably in 
humans too (34, 35). These same diets are also 
known to promote experimental carcinogenesis 
in rodents, and are considered risk factors for 
colorectal cancer in human populations (5, 6). 
It is usually considered that bile acids in the 
fecal stream can explain the promoting effect 
of these diets on colon cancer, but blood 
insulin may also explain the promotion by 
these diets (4). The present results support the 
idea that in humans, hyperinsulinemia and/or 
insulin resistance may explain the high risk of 
colorectal cancer associated with sedentary 
lifestyle, overfeeding, and nutriments cited 
above (4, 5, 6). 
 This study is the second to show a 
promotion of colon carcinogenesis by 
exogenous insulin. If nutritional studies, in 
progress in our laboratory, also show the 
promoting effect of endogenous insulin, it will 
be necessary to study the protection afforded by 
interventions that reduce insulinemia in 
humans. 
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